CancerNCT00251563
Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.
An observational study of Cancer, run by Nanjing Medical University at 1 site in China.
Trial summary
Environmental and genetic factors may play a role in the progression of cancer. The goal of this project is to establish a series of cross-sectional / case-control studies to evaluate risk factors of cancer in China. Read more about this study
- Who is it for?
- Ages 18 to 89 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer
- How many people
- Not given
- Where
- 1 siteChina
- Study dates
- Aug 2005to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- This is a study only of Chinese. Subjects will be allowed to participate if they self-identify as Chinese. The age range of the participants will be between 18 and 89 years. Individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.) will be allowed to participate. To participate in the study as the control, subjects should be confirmed without cancer.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Department of Pharmacology, Institute of Clinical Pharmacology, Nanjing Medical University
Nanjing, Jiangsu, 210029
Bin Wang, Ph.D, 0086-25-86862884, binwang@njmu.edu.cn
About this study
Environmental and genetic factors may play a role in the progression of cancer. The goal of this project is to establish a series of cross-sectional / case-control studies to evaluate risk factors of cancer in China.
Read the detailed description
This study is designed to investigate the epidemiologic, genetic, laboratory and clinical characterization of individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.). We will accrue approximately 1600 patients as experimental group. The control group consists of subjects who will be confirmed without cancer. We will explore the environmental (including family history, life style, diet, physical activity, neuropsychological functioning，plasma levels of oxidative stress factors, angiogenic factors, and tumor markers, etc.) and genetic (including oxidative stress factors and angiogenic factors, etc.) risk factors. We will study the association between various environmental risk factors with the clinical characterization and correlation between the genetic polymorphisms and the presence of various cancer.
- Conditions
- Cancer
- Keywords
- Cancer,Risk factors
- Medical subject headings
- Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2005 (estimated)
- Study startAug 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Nanjing Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
Sponsor and investigators
- Lead sponsor
- Nanjing Medical University
- Sponsor type
- University, hospital or other
- Investigators
- Bin Wang, Ph.D, Principal investigator, Department of Pharmacology, Institute of Clinical Pharmacology, Nanjing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00251563
- Sponsor's protocol ID
- ICP036
- Status last verified
- Nov 2005
- First submitted
- 9 Nov 2005
- Last updated
- 13 Oct 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.
- ClinicalTrials.gov ID
- NCT00251563
- Acronym / sponsor ID
- ICP036
- Conditions
- Cancer
- Keywords
- Cancer,Risk factors
- Study type
- Observational
- Recruitment status
- Unknown status
- Lead sponsor
- Nanjing Medical UniversityUniversity, hospital or other
- Study start
- Aug 2005
- First posted
- 10 Nov 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Environmental and genetic factors may play a role in the progression of cancer. The goal of this project is to establish a series of cross-sectional / case-control studies to evaluate risk factors of cancer in China.
Detailed description
This study is designed to investigate the epidemiologic, genetic, laboratory and clinical characterization of individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.). We will accrue approximately 1600 patients as experimental group. The control group consists of subjects who will be confirmed without cancer. We will explore the environmental (including family history, life style, diet, physical activity, neuropsychological functioning，plasma levels of oxidative stress factors, angiogenic factors, and tumor markers, etc.) and genetic (including oxidative stress factors and angiogenic factors, etc.) risk factors. We will study the association between various environmental risk factors with the clinical characterization and correlation between the genetic polymorphisms and the presence of various cancer.
Study design
- Observational model
- Case-control
- Time perspective
- Other
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- This is a study only of Chinese. Subjects will be allowed to participate if they self-identify as Chinese. The age range of the participants will be between 18 and 89 years. Individuals with cancer (gastric, colorectal, esophageal, liver, prostate, lung, breast and endometrial cancer, etc.) will be allowed to participate. To participate in the study as the control, subjects should be confirmed without cancer.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2006.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bin Wang, Ph.D principal investigator
Department of Pharmacology, Institute of Clinical Pharmacology, Nanjing Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Nanjing Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Oct 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Bin Wang, Ph.D (0086-25-86862884, binwang@njmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2006.